ADICET BIO INC (ACET:NASDAQ)
$5.61 -0.13 (-2.2648%)
Analysed ADICET BIO INC (ACET:NASDAQ) News Sources
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
18-08-2026
yahoo.com
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
27-08-2026
yahoo.com
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
31-08-2026
yahoo.com
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
02-09-2026
yahoo.com
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
03-09-2026
yahoo.com
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
03-09-2026
yahoo.com
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
25-09-2026
yahoo.com
Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients
28-09-2026
advfn.com
Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance
28-09-2026
advfn.com
Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
03-10-2026
marketbeat.com
What is the current price of ADICET BIO INC (ACET:NASDAQ)?
The current price of ADICET BIO INC (ACET:NASDAQ) is $5.61.
ADICET BIO INC (ACET:NASDAQ) absolute price change since previous trading day?
The absolute price change of ADICET BIO INC (ACET:NASDAQ) since the previous trading day is $-0.13.
ADICET BIO INC (ACET:NASDAQ) percentage price change since previous trading day?
The percentage price change of ADICET BIO INC (ACET:NASDAQ) since the previous trading day is -2.2648%.
What is the most recent average sentiment score for ADICET BIO INC (ACET:NASDAQ)?
The most recent average sentiment score for ADICET BIO INC (ACET:NASDAQ) is 73 out of 100.
What is the most recent average sentiment for ADICET BIO INC (ACET:NASDAQ)?
The most recent sentiment for ADICET BIO INC (ACET:NASDAQ) is .
SEC-8K** Filing Available For ADICET BIO INC (ACET:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.